“We seek to understand the molecular pathways that drive primary and metastatic brain tumors. Our goal is to identify new therapeutic targets that will help patients.”

-Priscilla Kaliopi Brastianos, MD

THE FIGHT AGAINST CANCER

The Central Nervous System Metastasis Program at Massachusetts General Hospital and Harvard Medical School, in collaboration with the Broad Institute of MIT and Harvard, has the following objectives:

(1) Identify and understand the molecular pathways driving brain metastases

(2) Identify novel therapeutic targets for patients with brain metastases

(3) Accelerate the application of our scientific findings to the clinical setting.

25 % of cancer patients that develop brain metastases

30 % of advanced HER2 positive breast cancers that develop brain metastases

40 % of advanced primary lung cancers that develop brain metastases

50 % of advanced triple negative breast cancers that develop brain metastases

50 % of advanced melanoma patients develop brain metastases

Research

GENOMICS

We aim to identify genetic drivers of recurrent primary, as well as metastatic brain tumors with large-scale genomic efforts.

TRANSLATIONAL RESEARCH

We seek to accelerate the application of our scientific findings to the clinical setting.

CLINICAL TRIALS

We strive to develop innovative therapeutic strategies for patients with primary and metastatic tumors.

TISSUE BANKING

With our national and international team of collaborators, we have created an extensive tissue bank of metastatic brain tumors.

Donate Now

Donate